HPV Integration Testing for Human Papillomavirus-Positive Women
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Locations
-
-
Hubei
-
Wuhan, Hubei, China, 430030
- Recruiting
- Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
Women aged 30-65 years old visiting the gynecologic clinic of hospital
Exclusion Criteria:
- Not providing informed consent
- previously confirmed CIN, cervical cancer, or other malignancies
- previous therapeutic procedure to cervix
- pregnancy
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
HPV-positive women,30-65 years of age
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Sensitivity and Specificity of the HPV integration screening test with comparison to HPV testing or TCT
Time Frame: 14 Months
|
14 Months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Chair: Ding Ma, MD, PhD, Huazhong University of Science and Technology
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CCS-02
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cervical Cancer
-
NCT03146039WithdrawnCervical Cancer | Cervical Cancer Stage | Cervical Cancer Stage IB2 | Cervical Cancer Stage IB1 | Cervical Cancer Stage I | Cervical Cancer Stage IB | Cervical Cancer Stage II | Cervical Cancer Stage IIa | Cervical Cancer, Stage IIB | Cervical Cancer, Stage III
-
NCT05093712WithdrawnStage IB3 Cervical Cancer FIGO 2018 | Stage II Cervical Cancer FIGO 2018 | Stage IIA Cervical Cancer FIGO 2018 | Stage IIA1 Cervical Cancer FIGO 2018 | Stage IIA2 Cervical Cancer FIGO 2018 | Stage IIB Cervical Cancer FIGO 2018 | Stage III Cervical Cancer FIGO 2018 | Stage IIIA Cervical Cancer FIGO 2018 | Stage IIIB Cervical Cancer FIGO 2018 | Stage IIIC Cervical Cancer FIGO 2018
-
NCT07196033RecruitingStage IIA Cervical Cancer FIGO 2018 | Stage IIB Cervical Cancer FIGO 2018 | Stage IIIA Cervical Cancer FIGO 2018 | Stage IIIB Cervical Cancer FIGO 2018 | Stage IVA Cervical Cancer FIGO 2018 | Stage IB Cervical Cancer FIGO 2018
-
NCT04574635Active, not recruitingCervical Adenosquamous Carcinoma | Cervical Squamous Cell Carcinoma, Not Otherwise Specified | Recurrent Cervical Carcinoma | Stage IB3 Cervical Cancer FIGO 2018 | Stage II Cervical Cancer FIGO 2018 | Stage IIA Cervical Cancer FIGO 2018 | Stage IIA1 Cervical Cancer FIGO 2018 | Stage IIA2 Cervical Cancer FIGO 2018 | Stage IIB Cervical Cancer FIGO 2018 | Stage III Cervical Cancer FIGO 2018
-
NCT01019278WithdrawnCervical Cancer | Stage IB Cervical Cancer | Stage IIA Cervical Cancer | Stage IIB Cervical Cancer | Stage III Cervical Cancer | Stage IVA Cervical Cancer
-
NCT07266350Not yet recruitingCervical Cancer Recurrent | Cervical Cancer Metastatic
-
NCT07143292Not yet recruitingCervical Cancer Recurrent | Cervical Cancer Metastatic
-
NCT00559377CompletedCervical Adenocarcinoma | Cervical Squamous Cell Carcinoma | Stage IB Cervical Cancer | Stage IIA Cervical Cancer | Stage IIB Cervical Cancer | Stage III Cervical Cancer | Stage IVA Cervical Cancer | Stage IVB Cervical Cancer
-
NCT04723095RecruitingCervical Large Cell Neuroendocrine Carcinoma | Cervical Neuroendocrine Carcinoma | Cervical Small Cell Carcinoma | Cervical Undifferentiated Carcinoma | Stage I Cervical Cancer AJCC v8 | Stage IA Cervical Cancer AJCC v8 | Stage IA1 Cervical Cancer AJCC v8 | Stage IA2 Cervical Cancer AJCC v8 | Stage IB Cervical Cancer AJCC v8 | Stage IB1 Cervical Cancer AJCC v8
-
NCT00054444CompletedCervical Adenocarcinoma | Cervical Squamous Cell Carcinoma | Stage IB Cervical Cancer | Stage IIA Cervical Cancer | Stage IIB Cervical Cancer | Stage III Cervical Cancer | Stage IVA Cervical Cancer
Clinical Trials on TCT,HPV,colposcopic inspection
-
NCT02576158UnknownCervical Cancer | Cervical Intraepithelial Neoplasia
-
NCT03961178UnknownPregnancy | Fertility | Precancerous Lesions | Human Papillomavirus Infection | Uterine Cervical Cancer | High Grade Intraepithelial Neoplasia | Conization
-
NCT03960879UnknownDNA Methylation | Uterine Cervical Cancer | High Grade Squamous Intraepithelial Lesions | Low Grade Squamous Intraepithelial Lesions
-
NCT03961191UnknownDNA Methylation | Uterine Cervical Cancer | High Grade Squamous Intraepithelial Lesions | Low Grade Squamous Intraepithelial Lesions
-
NCT05851079RecruitingCervical Intraepithelial Neoplasia Grade 2/3 | Cervical Lesion
-
NCT03055130UnknownInflammatory Bowel Diseases | HPV-Related Cervical Carcinoma | Cervical Neoplasm
-
NCT00667563CompletedCervical Cancer | Precancerous Condition | Nonneoplastic Condition
-
NCT05385406Recruiting
-
NCT04859530Recruiting